Managing the baby with a patent ductus arteriosus. More questions than answer?

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 90, Issue 3, 2005, Pages

  Fowlie, P W ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

DIURETIC THERAPY; HIGH RISK PATIENT; HUMAN; KIDNEY INJURY; LUNG DYSPLASIA; NECROTIZING ENTEROCOLITIS; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; SHORT SURVEY; WATER DEPRIVATION;

DUCTUS ARTERIOSUS, PATENT; EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PROGNOSIS;

EID: 17844392095     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2004.065946     Document Type: Short Survey

References (6)

1. http://www.thecochranelibrary.com.
2. Wyllie J. Treatment of patent ductus arteriosus. Semin Neonatal 2003;8:425-32.
3. Brooks JM, Travadi JN, Patole SK, et al. Is sirgical ligation of a patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005;90:F235-9.
4. UK Collaborative ECMO Trail Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation, Lancet 1996;348:75-82.
5. Bennett CC, Johnson A, Field DJ, Elbourne D. UK Collaborative ECMO Trial Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. Lancet 2001;357:1094-6.
6. Fergusson D, Aaron SD, Guyatt G, et al. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-4.